Replace the NOAEL and LOAEL with the BMDL01 and BMDL10

Although benchmark-dose methodology has existed for more than 20 years, benchmark doses (BMDs) still have not fully supplanted the no-observed-adverse-effect level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) as points of departure from the experimental dose–response range for setting acceptable exposure levels of toxic substances. Among the issues involved in replacing the NOAEL (LOAEL) with a BMD are (1) which added risk level(s) above background risk should be targeted as benchmark responses (BMRs), (2) whether to apply the BMD methodology to both carcinogenic and noncarcinogenic toxic effects, and (3) how to model continuous health effects that aren’t observed in a natural risk-based context like dichotomous health effects. This paper addresses these issues and recommends specific BMDs to replace the NOAEL and LOAEL.

[1]  D W Gaylor,et al.  The use of safety factors for controlling risk. , 1983, Journal of toxicology and environmental health.

[2]  K S Crump,et al.  A new method for determining allowable daily intakes. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[3]  J W Tukey,et al.  Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.

[4]  F. Mohammad,et al.  Behavioral and developmental effects in rats following in utero exposure to 2,4-D/2,4,5-t mixture. , 1986, Neurobehavioral toxicology and teratology.

[5]  D W Gaylor,et al.  Issues in qualitative and quantitative risk analysis for developmental toxicology. , 1988, Risk analysis : an official publication of the Society for Risk Analysis.

[6]  W Slikker,et al.  Risk assessment for neurotoxic effects. , 1990, Neurotoxicology.

[7]  Michael L. Dourson,et al.  Non cancer health endpoints approaches to quantitative risk assessment , 1991 .

[8]  W Leisenring,et al.  Statistical properties of the NOAEL. , 1992, Regulatory toxicology and pharmacology : RTP.

[9]  D W Gaylor,et al.  Incidence of developmental defects at the no observed adverse effect level (NOAEL). , 1992, Regulatory toxicology and pharmacology : RTP.

[10]  L. Ryan,et al.  Statistical model for fetal death, fetal weight, and malformation in developmental toxicity studies. , 1993, Teratology.

[11]  R L Kodell,et al.  Upper confidence limits on excess risk for quantitative responses. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[12]  Michael L. Dourson,et al.  Noncancer health endpoints Approaches to quantitative risk assessment , 1993 .

[13]  C. Kimmel,et al.  Dose-response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[14]  B C Allen,et al.  Dose-response assessment for developmental toxicity. III. Statistical models. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[15]  B C Allen,et al.  Dose-response assessment for developmental toxicity. I. Characterization of database and determination of no observed adverse effect levels. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[16]  Kenny S. Crump,et al.  Calculation of Benchmark Doses from Continuous Data , 1995 .

[17]  R J Kavlock,et al.  Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose. , 1995, Regulatory toxicology and pharmacology : RTP.

[18]  B C Allen,et al.  Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. , 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[19]  R L Kodell,et al.  Neurotoxicity modeling for risk assessment. , 1995, Regulatory toxicology and pharmacology : RTP.

[20]  D. Gaylor.  Quantalization of continuous data for benchmark dose estimation. , 1996, Regulatory toxicology and pharmacology : RTP.

[21]  C. Kimmel,et al.  Non-cancer risk assessment for nickel compounds: issues associated with dose-response modeling of inhalation and oral exposures. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  G. Alexeeff,et al.  The use of benchmark dose methodology with acute inhalation lethality data. , 1999, Regulatory toxicology and pharmacology : RTP.

[23]  R. Kodell,et al.  A Comparison of Methods of Benchmark-Dose Estimation for Continuous Response Data , 1999 .

[24]  R L Kodell,et al.  Incorporating model uncertainties along with data uncertainties in microbial risk assessment. , 2000, Regulatory toxicology and pharmacology : RTP.

[25]  Paul M Schlosser,et al.  Benchmark dose risk assessment for formaldehyde using airflow modeling and a single-compartment, DNA-protein cross-link dosimetry model to estimate human equivalent doses. , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[26]  Salomon Sand,et al.  The Benchmark Dose Method—Review of Available Models, and Recommendations for Application in Health Risk Assessment , 2003, Critical reviews in toxicology.

[27]  Walter W Piegorsch,et al.  Confidence Bands for Low‐Dose Risk Estimation with Quantal Response Data , 2003, Biometrics.

[28]  R. Kodell,et al.  Quantitative Risk Assessment for Developmental Neurotoxic Effects , 2004, Risk analysis : an official publication of the Society for Risk Analysis.

[29]  Matthew W Wheeler,et al.  Model Uncertainty and Risk Estimation for Experimental Studies of Quantal Responses , 2005, Risk analysis : an official publication of the Society for Risk Analysis.

[30]  R. Webster West,et al.  Changepoint alternatives to the NOAEL , 2005 .

[31]  Ralph L. Kodell.  Managing uncertainty in health risk assessment , 2005 .